Opportunity Nox: The Future of NADPH Oxidases as Therapeutic Targets in Cardiovascular Disease

Cardiovascular Therapeutics

Volumn 31, Issue 3, 2013, Pages 125-137

  Streeter, Jennifer ^a   Thiel, William ^a   Brieger, Kate ^a   Miller Jr , Francis J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Aptamers; Cardiovascular disease; NADPH oxidase; New therapeutics

Indexed keywords

ADALIMUMAB; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; APOCYNIN; ASCORBIC ACID; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; PR 39; PROTEIN P22; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SMALL INTERFERING RNA;

CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; COMPLEX FORMATION; ENZYME ACTIVATION; HUMAN; LIGAND BINDING; MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

CARDIOVASCULAR DISEASES; ELECTRON TRANSPORT; HUMANS; NADPH OXIDASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SELEX APTAMER TECHNIQUE; SIGNAL TRANSDUCTION;

EID: 84876500601     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00310.x     Document Type: Review

References (153)

1. Steinbeck MJ, Kim JK, Trudeau MJ, et al. Involvement of hydrogen peroxide in the differentiation of clonal HD-11EM cells into osteoclast-like cells. J Cell Physiol 1998;176:574-587.
2. Grewal JS, Mukhin YV, Garnovskaya MN, et al. Serotonin 5-HT2A receptor induces TGF-beta1 expression in mesangial cells via ERK: Proliferative and fibrotic signals. Am J Physiol 1999;276(6 Pt 2):F922-F930.
3. Brar SS, Kennedy TP, Sturrock AB, et al. An NAD(P)H oxidase regulates growth and transcription in melanoma cells. Am J Physiol Cell Physiol 2002;282:C1212-C1224.
4. Sundaresan M, Yu ZX, Ferrans VJ, et al. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 1995;270:296-299.
5. Brar SS, Kennedy TP, Sturrock AB, et al. NADPH oxidase promotes NF-kappaB activation and proliferation in human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2002;282:L782-L795.
6. Lundqvist-Gustafsson H, Bengtsson T. Activation of the granule pool of the NADPH oxidase accelerates apoptosis in human neutrophils. J Leukoc Biol 1999;65:196-204.
7. Wu RF, Gu Y, Xu YC, et al. Human immunodeficiency virus type 1 Tat regulates endothelial cell actin cytoskeletal dynamics through PAK1 activation and oxidant production. J Virol 2004;78:779-789.
8. Rueckschloss U, Villmow M, Klockner U. NADPH oxidase-derived superoxide impairs calcium transients and contraction in aged murine ventricular myocytes. Exp Gerontol 2010;45:788-796.
9. Bendall JK, Cave AC, Heymes C, et al. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002;105:293-296.
10. Fukui T, Lassegue B, Kai H, et al. Cytochrome b-558 alpha-subunit cloning and expression in rat aortic smooth muscle cells. Biochim Biophys Acta 1995;1231:215-219.
11. Jones SA, O'Donnell VB, Wood JD, et al. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol 1996;271:H1626-H1634.
12. Pagano PJ, Clark JK, Cifuentes-Pagano ME, et al. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA 1997;94:14483-14488.
13. Baehner RL, Karnovsky ML. Deficiency of reduced nicotinamide-adenine dinucleotide oxidase in chronic granulomatous disease. Science 1968;162:1277-1279.
14. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004;4:181-189.
15. Takac I, Schroder K, Zhang L, et al. The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J Biol Chem 2011;286:13304-13313.
16. BelAiba RS, Djordjevic T, Petry A, et al. NOX5 variants are functionally active in endothelial cells. Free Radic Biol Med 2007;42:446-459.
17. Banfi B, Molnar G, Maturana A, et al. A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem 2001;276:37594-37601.
18. Lassegue B, Griendling KK. NADPH oxidases: Functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 2010;30:653-661.
19. Sedeek M, Hebert RL, Kennedy CR, et al. Molecular mechanisms of hypertension: Role of Nox family NADPH oxidases. Curr Opin Nephrol Hypertens 2009;18:122-127.
20. Sorescu D, Weiss D, Lassegue B, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002;105:1429-1435.
21. Heymes C, Bendall JK, Ratajczak P, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003;41:2164-2171.
22. Szocs K, Lassegue B, Sorescu D, et al. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 2002;22:21-27.
23. Dudley SC, Jr., Hoch NE, McCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: Role of the NADPH and xanthine oxidases. Circulation 2005;112:1266-1273.
24. Brandes RP. Role of NADPH oxidases in the control of vascular gene expression. Antioxid Redox Signal 2003;5:803-811.
25. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: Specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physio 2003;285:R277-R297.
26. Jiang F, Zhang Y, Dusting GJ. NADPH oxidase-mediated redox signaling: Roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol Rev 2011;63:218-242.
27. Durand E, Scoazec A, Lafont A, et al. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: A clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation 2004;109:2503-2506.
28. Pendyala S, Usatyuk PV, Gorshkova IA, et al. Regulation of NADPH oxidase in vascular endothelium: The role of phospholipases, protein kinases, and cytoskeletal proteins. Antioxid Redox Signal 2009;11:841-860.
29. Lee K, Esselman WJ. Inhibition of PTPs by H(2)O(2) regulates the activation of distinct MAPK pathways. Free Radic Biol Med 2002;33:1121-1132.
30. Schwartz SM, deBlois D, O'Brien ER. The intima. Soil for atherosclerosis and restenosis. Circ Res 1995;77:445-465.
31. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 2010;459:923-939.
32. Riddell DR, Owen JS. Nitric oxide and platelet aggregation. Vitam Horm 1999;57:25-48.
33. Violi F, Basili S, Nigro C, et al. Role of NADPH oxidase in atherosclerosis. Future Cardiol 2009;5:83-92.
34. Kubes P. Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. Microcirculation 1995;2:235-244.
35. Hwang J, Saha A, Boo YC, et al. Oscillatory shear stress stimulates endothelial production of O2- from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion. J Biol Chem 2003;278:47291-47298.
36. Sorescu GP, Song H, Tressel SL, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res 2004;95:773-779.
37. Channon KM. Oxidative stress and coronary plaque stability. Arterioscler Thromb Vasc Biol 2002;22:1751-1752.
38. Irani K. Oxidant signaling in vascular cell growth, death, and survival: A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000;87:179-183.
39. Daub K, Seizer P, Stellos K, et al. Oxidized LDL-activated platelets induce vascular inflammation. Semin Thromb Hemost 2010;36:146-156.
40. Lee MY, San Martin A, Mehta PK, et al. Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation. Arterioscler Thromb Vasc Biol 2009;29:480-487.
41. Sheehan AL, Carrell S, Johnson B, et al. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 2011;216:321-326.
42. Dikalova A, Clempus R, Lassegue B, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005;112:2668-2676.
43. Matsuno K, Yamada H, Iwata K, et al. Nox1 is involved in angiotensin II-mediated hypertension: A study in Nox1-deficient mice. Circulation 2005;112:2677-2685.
44. Gavazzi G, Banfi B, Deffert C, et al. Decreased blood pressure in NOX1-deficient mice. FEBS Lett 2006;580:497-504.
45. Gavazzi G, Deffert C, Trocme C, et al. NOX1 deficiency protects from aortic dissection in response to angiotensin II. Hypertension 2007;50:189-196.
46. Chen XL, Zhang Q, Zhao R, et al. Rac1 and superoxide are required for the expression of cell adhesion molecules induced by tumor necrosis factor-alpha in endothelial cells. J Pharmacol Exp Ther 2003;305:573-580.
47. Gertzberg N, Neumann P, Rizzo V, et al. NAD(P)H oxidase mediates the endothelial barrier dysfunction induced by TNF-alpha. Am J Physiol Lung Cell Mol Physiol 2004;286:L37-L48.
48. Judkins CP, Diep H, Broughton BR, et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol 2010;298:H24-H32.
49. Jung O, Schreiber JG, Geiger H, et al. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 2004;109:1795-1801.
50. Wang HD, Xu S, Johns DG, et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 2001;88:947-953.
51. Satoh M, Ogita H, Takeshita K, et al. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci USA 2006;103:7432-7437.
52. Krijnen PA, Meischl C, Hack CE, et al. Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol 2003;56:194-199.
53. Looi YH, Grieve DJ, Siva A, et al. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 2008;51:319-325.
54. Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis 2010;45:246-265.
55. Park HS, Chun JN, Jung HY, et al. Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. Cardiovasc Res 2006;72:447-455.
56. Chen K, Kirber MT, Xiao H, et al. Regulation of ROS signal transduction by NADPH oxidase 4 localization. J Cell Biol 2008;181:1129-1139.
57. Ushio-Fukai M. Redox signaling in angiogenesis: Role of NADPH oxidase. Cardiovasc Res 2006;71:226-235.
58. Ray R, Murdoch CE, Wang M, et al. Endothelial nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 2011;31:1368-1376.
59. Liu Y, Bubolz AH, Mendoza S, et al. H2O2 is the transferrable factor mediating flow-induced dilation in human coronary arterioles. Circ Res 2011;108:566-573.
60. Zhang M, Brewer AC, Schroder K, et al. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci USA 2010;107:18121-18126.
61. Nishiyama A, Yao L, Nagai Y, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004;43:841-848.
62. Kawahara T, Quinn MT, Lambeth JD. Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes. BMC Evol Biol 2007;7:109.
63. De Deken X, Wang D, Many MC, et al. Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J Biol Chem 2000;275:23227-23233.
64. Montezano AC, Burger D, Paravicini TM, et al. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ Res 2010;106:1363-1373.
65. Jay DB, Papaharalambus CA, Seidel-Rogol B, et al. Nox5 mediates PDGF-induced proliferation in human aortic smooth muscle cells. Free Radic Biol Med 2008;45:329-335.
66. Guzik TJ, Chen W, Gongora MC, et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol 2008;52:1803-1809.
67. Modlinger P, Chabrashvili T, Gill PS, et al. RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension 2006;47:238-244.
68. Jose G S, Moreno MU, Olivan S, et al. Functional effect of the p22phox -930A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension. Hypertension 2004;44:163-169.
69. Goliasch G, Wiesbauer F, Grafl A, et al. The effect of p22-PHOX (CYBA) polymorphisms on premature coronary artery disease (
70. Thomas M, Gavrila D, McCormick ML, et al. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation 2006;114:404-413.
71. Cifuentes ME, Rey FE, Carretero OA, et al. Upregulation of p67(phox) and gp91(phox) in aortas from angiotensin II-infused mice. Am J Physiol Heart Circ Physiol 2000;279:H2234-H2240.
72. Drummond GR, Selemidis S, Griendling KK, et al. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011;10:453-471.
73. Niu XL, Madamanchi NR, Vendrov AE, et al. Nox activator 1: A potential target for modulation of vascular reactive oxygen species in atherosclerotic arteries. Circulation 2010;121:549-559.
74. Honjo T, Otsui K, Shiraki R, et al. Essential role of NOXA1 in generation of reactive oxygen species induced by oxidized low-density lipoprotein in human vascular endothelial cells. Endothelium 2008;15:137-141.
75. Choi H, Leto TL, Hunyady L, et al. Mechanism of angiotensin II-induced superoxide production in cells reconstituted with angiotensin type 1 receptor and the components of NADPH oxidase. J Biol Chem 2008;283:255-267.
76. Kiss PJ, Knisz J, Zhang Y, et al. Inactivation of NADPH oxidase organizer 1 results in severe imbalance. Curr Biol 2006;16:208-213.
77. Banfi B, Malgrange B, Knisz J, et al. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem 2004;279:46065-46072.
78. Kikuchi H, Hikage M, Miyashita H, et al. NADPH oxidase subunit, gp91(phox) homologue, preferentially expressed in human colon epithelial cells. Gene 2000;254:237-243.
79. Touyz RM, Briones AM, Sedeek M, et al. NOX isoforms and reactive oxygen species in vascular health. Mol Interv 2011;11:27-35.
80. Montezano AC, Burger D, Ceravolo GS, et al. Novel Nox homologues in the vasculature: Focusing on Nox4 and Nox5. Clin Sci 2011;120:131-141.
81. Sirker A, Zhang M, Shah AM. NADPH oxidases in cardiovascular disease: Insights from in vivo models and clinical studies. Basic Res Cardiol 2011;106:735-747.
82. Cross AR, Segal AW. The NADPH oxidase of professional phagocytes-prototype of the NOX electron transport chain systems. Biochim Biophys Acta 2004;1657:1-22.
83. San Martin A, Foncea R, Laurindo FR, et al. Nox1-based NADPH oxidase-derived superoxide is required for VSMC activation by advanced glycation end-products. Free Radic Biol Med 2007;42:1671-1679.
84. Tabet F, Schiffrin EL, Callera GE, et al. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res 2008;103:149-158.
85. Rodriguez AI, Gangopadhyay A, Kelley EE, et al. HO-1 and CO decrease platelet-derived growth factor-induced vascular smooth muscle cell migration via inhibition of Nox1. Arterioscler Thromb Vasc Biol 2010;30:98-104.
86. Lee SH, Park DW, Park SC, et al. Calcium-independent phospholipase A2beta-Akt signaling is involved in lipopolysaccharide-induced NADPH oxidase 1 expression and foam cell formation. J Immunol 2009;183:7497-7504.
87. Ryu J, Lee CW, Shin JA, et al. FcgammaRIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. Cardiovasc Res 2007;75:555-565.
88. Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. A status report on RNAi therapeutics. Silence 2010;1:14.
89. Cevik MO, Katsuyama M, Kanda S, et al. The AP-1 site is essential for the promoter activity of NOX1/NADPH oxidase, a vascular superoxide-producing enzyme: Possible involvement of the ERK1/2-JunB pathway. Biochem Biophys Res Commun 2008;374:351-355.
90. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol Rev 2007;87:245-313.
91. Suzuki S, Kumatori A, Haagen IA, et al. PU.1 as an essential activator for the expression of gp91(phox) gene in human peripheral neutrophils, monocytes, and B lymphocytes. Proc Natl Acad Sci USA 1998;95:6085-6090.
92. Miller AA, Drummond GR, De Silva TM, et al. NADPH oxidase activity is higher in cerebral versus systemic arteries of four animal species: Role of Nox2. Am J Physiol Heart Circ Physiol 2009;296:H220-H225.
93. Chabrashvili T, Kitiyakara C, Blau J, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003;285:R117-R124.
94. Miller FJ, Jr., Filali M, Huss GJ, et al. Cytokine activation of nuclear factor kappa B in vascular smooth muscle cells requires signaling endosomes containing Nox1 and ClC-3. Circ Res 2007;101:663-671.
95. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-305.
96. Cauza E, Cauza K, Hanusch-Enserer U, et al. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002;114:1004-1007.
97. Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006;33:2440-2446.
98. Vis M, Nurmohamed MT, Wolbink G, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005;32:252-255.
99. Helmcke I, Heumuller S, Tikkanen R, et al. Identification of structural elements in Nox1 and Nox4 controlling localization and activity. Antioxid Redox Signal 2009;11:1279-1287.
100. Kawahara T, Lambeth JD. Phosphatidylinositol (4, 5)-bisphosphate modulates Nox5 localization via an N-terminal polybasic region. Mol Biol Cell 2008;19:4020-4031.
101. Spencer NY, Yan Z, Boudreau RL, et al. Control of hepatic nuclear superoxide production by glucose 6-phosphate dehydrogenase and NADPH oxidase-4. J Biol Chem 2011;286:8977-8987.
102. Kuroda J, Ago T, Matsushima S, et al. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci USA 2010;107:15565-15570.
103. Miller FJ, Jr., Chu X, Stanic B, et al. A differential role for endocytosis in receptor-mediated activation of Nox1. Antioxid Redox Signal 2010;12:583-593.
104. Casbon AJ, Allen LA, Dunn KW, et al. Macrophage NADPH oxidase flavocytochrome B localizes to the plasma membrane and Rab11-positive recycling endosomes. J Immunol 2009;182:2325-2339.
105. Perrotta I, Sciangula A, Perrotta E, et al. Ultrastructural analysis and electron microscopic localization of Nox4 in healthy and atherosclerotic human aorta. Ultrastruct Pathol 2011;35:1-6.
106. Kurten RC. Sorting motifs in receptor trafficking. Adv Drug Deliv Rev 2003;55:1405-1419.
107. Hofmann MW, Honing S, Rodionov D, et al. The leucine-based sorting motifs in the cytoplasmic domain of the invariant chain are recognized by the clathrin adaptors AP1 and AP2 and their medium chains. J Biol Chem 1999;274:36153-36158.
108. von Lohneysen K, Noack D, Wood MR, et al. Structural insights into Nox4 and Nox2: Motifs involved in function and cellular localization. Mol Cell Biol 2010;30:961-975.
109. El-Benna J, Dang PM, Gougerot-Pocidalo MA. Priming of the neutrophil NADPH oxidase activation: Role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin Immunopathol 2008;30:279-289.
110. Banfi B, Clark RA, Steger K, et al. Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem 2003;278:3510-3513.
111. Ambasta RK, Schreiber JG, Janiszewski M, et al. Noxa1 is a central component of the smooth muscle NADPH oxidase in mice. Free Radic Biol Med 2006;41:193-201.
112. Diatchuk V, Lotan O, Koshkin V, et al. Inhibition of NADPH oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds. J Biol Chem 1997;272:13292-13301.
113. Stolk J, Hiltermann TJ, Dijkman JH, et al. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 1994;11:95-102.
114. Dharmarajah J, Arthur JF, Sobey CG, et al. The anti-platelet effects of apocynin in mice are not mediated by inhibition of NADPH oxidase activity. Naunyn Schmiedebergs Arch Pharmacol 2010;382:377-384.
115. Heumuller S, Wind S, Barbosa-Sicard E, et al. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008;51:211-217.
116. Williams HC, Griendling KK. NADPH oxidase inhibitors: New antihypertensive agents?J Cardiovasc Pharmacol 2007;50:9-16.
117. Rey FE, Cifuentes ME, Kiarash A, et al. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res 2001;89:408-414.
118. Jacobson GM, Dourron HM, Liu J, et al. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ Res 2003;92:637-643.
119. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002;22:300-305.
120. Rueckschloss U, Galle J, Holtz J, et al. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: Antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 2001;104:1767-1772.
121. Diebold BA, Fowler B, Lu J, et al. Antagonistic cross-talk between Rac and Cdc42 GTPases regulates generation of reactive oxygen species. J Biol Chem 2004;279:28136-28142.
122. Bokoch GM, Diebold B, Kim JS, et al. Emerging evidence for the importance of phosphorylation in the regulation of NADPH oxidases. Antioxid Redox Signal 2009;11:2429-2441.
123. Faust LR, el Benna J, Babior BM, et al. The phosphorylation targets of p47phox, a subunit of the respiratory burst oxidase. Functions of the individual target serines as evaluated by site-directed mutagenesis. J Clin Invest 1995;96:1499-1505.
124. Raad H, Paclet MH, Boussetta T, et al. Regulation of the phagocyte NADPH oxidase activity: Phosphorylation of gp91phox/NOX2 by protein kinase C enhances its diaphorase activity and binding to Rac2, p67phox, and p47phox. FASEB J 2009;23:1011-1022.
125. Idris I, Donnelly R. Protein kinase C beta inhibition: A novel therapeutic strategy for diabetic microangiopathy. Diab Vasc Dis Res 2006;3:172-178.
126. O'Donnell BV, Tew DG, Jones OT, et al. Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. Biochem J 1993;290:41-49.
127. Majander A, Finel M, Wikstrom M. Diphenyleneiodonium inhibits reduction of iron-sulfur clusters in the mitochondrial NADH-ubiquinone oxidoreductase (Complex I). J Biol Chem 1994;269:21037-21042.
128. DeCoursey TE, Morgan D, Cherny VV. The voltage dependence of NADPH oxidase reveals why phagocytes need proton channels. Nature 2003;422:531-534.
129. Moreland JG, Davis AP, Bailey G, et al. Anion channels, including ClC-3, are required for normal neutrophil oxidative function, phagocytosis, and transendothelial migration. J Biol Chem 2006;281:12277-12288.
130. Lamb FS, Moreland JG, Miller FJ, Jr.Electrophysiology of reactive oxygen production in signaling endosomes. Antioxid Redox Signal 2009;11:1335-1347.
131. Chu X, Filali M, Stanic B, et al. A critical role for chloride channel-3 (CIC-3) in smooth muscle cell activation and neointima formation. Arterioscler Thromb Vasc Biol 2011;31:345-351.
132. Czernichow S, Bertrais S, Blacher J, et al. Effect of supplementation with antioxidants upon long-term risk of hypertension in the SU.VI.MAX study: Association with plasma antioxidant levels. J Hypertens 2005;23:2013-2018.
133. McQueen MJ, Lonn E, Gerstein HC, et al. The HOPE (Heart Outcomes Prevention Evaluation) study and its consequences. Scand J Clin Lab Invest Suppl 2005;240:143-156.
134. Maxwell S, Greig L. Anti-oxidants-a protective role in cardiovascular disease?Expert Opin Pharmacother 2001;2:1737-1750.
135. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: The Women's Health Study: A randomized controlled trial. JAMA 2005;294:56-65.
136. Gavrila D, Li WG, McCormick ML, et al. Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005;25:1671-1677.
137. Chu Y, Iida S, Lund DD, et al. Gene transfer of extracellular superoxide dismutase reduces arterial pressure in spontaneously hypertensive rats: Role of heparin-binding domain. Circ Res 2003;92:461-468.
138. Durand E, Al Haj Zen A, Addad F, et al. Adenovirus-mediated gene transfer of superoxide dismutase and catalase decreases restenosis after balloon angioplasty. J Vasc Res 2005;42:255-265.
139. Taylor RM, Maaty WS, Lord CI, et al. Cloning, sequence analysis and confirmation of derived gene sequences for three epitope-mapped monoclonal antibodies against human phagocyte flavocytochrome b. Mol Immunol 2007;44:625-37.
140. Zhang L, Nguyen MV, Lardy B, et al. New insight into the Nox4 subcellular localization in HEK293 cells: First monoclonal antibodies against Nox4. Biochimie 2011;93:457-468.
141. Brown SJ, Gianni D, Bokoch G, et al. Probe Report for NOX1 Inhibitors, in Probe Reports from the NIH Molecular Libraries Program 2010: Bethesda (MD).
142. Gianni D, Taulet N, Zhang H, et al. A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells. ACS Chem Biol 2010;5:981-993.
143. Kume A, Dinauer MC, Gene therapy for chronic granulomatous disease. J Lab Clin Med 1999;135:122-128.
144. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249:505-510.
145. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818-822.
146. Thiel KW, Giangrande PH. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 2009;19:209-222.
147. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010;9:537-550.
148. Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18:305-319.
149. Giangrande PH, Zhang J, Tanner A, et al. Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc Natl Acad Sci USA 2007;104:12988-12993.
150. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-132.
151. Dyke CK, Steinhubl SR, Kleiman NS, et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006;114:2490-2497.
152. Zhou J, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 2011;21:1-10.
153. McNamara JO, II, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24:1005-1015.